Transgenic mice for human genome antibodies
Ended Definitive Contract Awarded Last action
- Contract number
- 75D30122C14450
- Awardee
-
Abcellera Biologics Inc. UEI D3LSBFZ6MXE3
- Awarding agency
-
CDC Pittsburgh
Centers for Disease Control and Prevention, Department of Health and Human Services
- Obligated
- $884,000
Award facts
- Opportunity
-
- Using Transgenic Mouse to Generate Human Antibodies Solicitation · 75D30122Q74781 · Posted May 17, 2022
- Contract value 100% obligated
- $884,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- 8820 Live Animals, Not Raised For Food
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Atlanta, GA 30329, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $196,000 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $492,000 | |
| Original award | $196,000 |
About this award
The Centers for Disease Control and Prevention awarded Abcellera Biologics Inc. a definitive fixed price contract valued at $884,000 to provide a transgenic mouse model capable of generating humanized antibodies against influenza viruses. The original solicitation sought proposals for a mouse engineered with human immunoglobulin gene segments to better recapitulate the human antibody repertoire when testing candidate virus strains and developing antibodies. Under the contract, Abcellera will supply the CDC's Influenza Division with 50 mice in the first six months and up to an additional 250 mice over the following 18 months period. The mouse model must generate humanized antibodies against influenza and Abcellera must provide any required licenses or documentation for use of the technology from September 2022 through August 2024. The prime contractor will perform all work in Atlanta, Georgia for the CDC, which seeks to evaluate if antibodies from the humanized mouse model can help assess vaccine candidates and develop new antibodies to fight influenza.
Quick answers
Who was awarded contract 75D30122C14450?
75D30122C14450 was awarded to Abcellera Biologics Inc. by CDC Pittsburgh (Centers for Disease Control and Prevention) on August 3, 2022.
How much is contract 75D30122C14450 worth?
The government has obligated $884,000 on 75D30122C14450.
Was contract 75D30122C14450 competed?
The extent of competition for 75D30122C14450 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award